"Pfizer Moves RA, Pain Drugs Into Phase III" | Arthritis Information

From fiercebiotech:

http://www.fiercebiotech.com/story/pfizer-moves-ra-pain-drugs-phase-iii/2009-04-02

"In a pipeline update released today, Pfizer said Phase III clinical trials for two new molecular entities. The first is a JAK inhibitor (CP-690,550), an rheumatoid arthritis drug. It's also conducting Phase III trials of tanezumab, a fully-humanized monoclonal antibody which reduces pain in patients with osteoarthritis of the knee." From the 'update' link in the article:

http://www.fiercebiotech.com/press-releases/pfizer-development-pipeline-shows-advances-high-priority-disease-areas

"Earlier this year, Pfizer started Phase 3 studies in a first-in-class JAK inhibitor (CP-690,550), the first orally-administered, disease-modifying antirheumatic drug (DMARD) for rheumatoid arthritis in 10 years, based on promising Phase 2 efficacy and safety data." I went to clinicaltrials.gov and saw the trials that had been completed - but none had results posted. Search "CP-690,550" and they all come up - completed, active, recruiting, withdrawn. Suzanne2009-04-05 08:10:38I wonder what this means?

Pip

I found this release about another JAK inhibitor:

http://www.earthtimes.org/articles/show/incytes-jak-inhibitor-demonstrates-rapid,594555.shtml

"Incyte Corporation (Nasdaq:INCY) announced today the presentation of clinical results from a 28-day Phase IIa trial of INCB18424, its orally available janus kinase (JAK) inhibitor, in patients with rheumatoid arthritis (RA). Results from the 50-patient placebo-controlled trial demonstrated that three of the four doses of INCB18424 evaluated (15 mg BID, 25 mg BID and 50 mg QD) produced impressive clinical benefits and all of the doses were well tolerated." Suzanne2009-04-05 08:56:27More on the same:
http://www.genengnews.com/news/bnitem.aspx?name=44233154

From the researcher:
"Dr. Moreland stated, "Results from this initial Phase IIa trial suggest that INCB18424, a novel oral JAK inhibitor, has the potential to be at least as effective as currently available RA therapies, including the widely used injectable biologicals. I look forward to participating in the next phase of clinical trials and seeing this new class of potent oral anti-inflammatory agents with an exciting mechanism of action progress through clinical development."" Suzanne-

You are quite the researcher!!!!